AQLT - ETF AI Analysis
Top Page
iShares MSCI Global Quality Factor ETF (AQLT)
Rating:67Neutral
Price Target:―
Positive Factors
Strong Overall Year-to-Date Performance
The ETF has delivered solid gains so far this year, suggesting its quality-focused strategy has been working well for investors.
High-Quality Tech Leaders in Top Holdings
Several of the largest positions, including major technology and semiconductor companies, have shown strong performance and helped drive the fund’s returns.
Reasonable Expense Ratio
The fund’s expense ratio is relatively low for an actively tilted, factor-based global ETF, allowing investors to keep more of their returns over time.
Negative Factors
Heavy U.S. and Technology Concentration
A large share of the portfolio is in U.S. stocks and technology companies, which can increase risk if that market or sector experiences a downturn.
Some Major Holdings Are Underperforming
A few of the biggest positions, including well-known technology and communication names, have shown weak or negative performance this year, which can drag on the fund’s results.
Recent Short-Term Weakness
The ETF has slipped slightly over the past month, indicating that it can be sensitive to short-term market pullbacks even with its quality focus.
AQLT vs. SPDR S&P 500 ETF (SPY)
AUM332.41M
RegionGlobal
Expense Ratio0.20%
Beta0.94
IssueriShares
Inception DateDec 11, 2024
Dividend YieldN/A
Asset ClassEquity
Index TrackedMSCI ACWI Quality
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume17,906
30 Day Avg. Volume43,863
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
38.17Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering376
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AQLT Summary
The iShares MSCI Global Quality Factor ETF (AQLT) tracks the MSCI ACWI Quality index, which focuses on strong, financially healthy companies from around the world, with most of its holdings in the U.S. It owns well-known names like Apple and Microsoft, along with other large global firms, and leans heavily toward technology and health care. Investors might consider AQLT if they want broad global stock exposure while tilting toward companies with steady earnings and solid balance sheets. A key risk is that it can still rise and fall with the overall stock market and is quite dependent on large tech-related companies.
How much will it cost me?The iShares MSCI Global Quality Factor ETF (AQLT) has an expense ratio of 0.20%, which means you’ll pay $2 per year for every $1,000 invested. This is lower than average for actively managed funds but slightly higher than many passively managed ETFs, as it focuses on a specialized strategy targeting high-quality global stocks.
What would affect this ETF?The iShares MSCI Global Quality Factor ETF (AQLT) could benefit from continued growth in the technology sector, which makes up a significant portion of its holdings, as well as strong performance from its top companies like Nvidia, Apple, and Microsoft. However, rising interest rates or global economic slowdowns could negatively impact growth-focused sectors like technology and communication services, which are heavily weighted in this ETF. Regulatory changes affecting major tech companies or geopolitical tensions in key markets could also pose risks to future performance.
AQLT Top 10 Holdings
AQLT’s story is all about high-quality global growth, with Big Tech firmly in the driver’s seat. Microsoft and Nvidia are doing much of the heavy lifting, riding strong demand for cloud and AI, while ASML adds extra fuel from the semiconductor side. Apple looks steadier but has lost a bit of steam lately, and Meta has been more of a wobble, tempering some of the upside. Eli Lilly and Johnson & Johnson provide a health care ballast, but overall this is a globally diversified fund that leans heavily on U.S.-led tech strength.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Microsoft | 5.72% | $18.93M | $3.71T | 0.95% | 79 Outperform | |
| Apple | 5.12% | $16.95M | $4.67T | 33.49% | 79 Outperform | |
| Nvidia | 4.98% | $16.51M | $5.55T | 37.92% | 76 Outperform | |
| Meta Platforms | 4.32% | $14.30M | $1.57T | -18.03% | 76 Outperform | |
| Broadcom | 4.16% | $13.77M | $1.70T | 6.87% | 76 Outperform | |
| Eli Lilly & Co | 2.85% | $9.45M | $1.08T | 58.05% | 72 Outperform | |
| ASML Holding NV | 2.50% | $8.27M | €560.52B | 115.72% | 76 Outperform | |
| Alphabet Class A | 2.33% | $7.73M | $4.12T | 44.02% | 85 Outperform | |
| Visa | 2.26% | $7.49M | $700.27B | 9.28% | 70 Outperform | |
| Johnson & Johnson | 1.93% | $6.39M | $663.28B | 54.25% | 78 Outperform |
AQLT Technical Analysis
Positive
―
Price Trends
31.60
Positive
31.17
Positive
29.78
Positive
Market Momentum
0.07
Positive
52.72
Neutral
46.65
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For AQLT, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 32.04, equal to the 50-day MA of 31.60, and equal to the 200-day MA of 29.78, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 52.72 is Neutral, neither overbought nor oversold. The STOCH value of 46.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AQLT.
AQLT Peer Comparison
Comparison Results
Performance Comparison
AQLT
iShares MSCI Global Quality Factor ETF
31.96
5.83
22.31%
RGEF
Rockefeller Global Equity ETF
―
―
―
KAT
Scharf ETF
―
―
―
DWLD
Davis Select Worldwide Etf
―
―
―
RGLO
Global Equity Active ETF
―
―
―
JSTC
Adasina Social Justice All Cap Global ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents